Seven Bridges

The company's core offering is the Seven Bridges Platform, a cloud-based ecosystem designed for bioinformatic analyses. This platform provides researchers with access to datasets, analytic workflows, algorithms, and cloud-computing infrastructure. It serves a diverse client base that includes academic institutions, biotechnology companies, government bodies, hospitals, and pharmaceutical firms. The business model focuses on providing end-to-end bioinformatic solutions that facilitate the entire research lifecycle, from data storage and analysis to collaborative interpretation of results. This enables clients to accelerate drug discovery, biomarker identification, and the development of diagnostics.

The platform's key features include its ability to operate on major public cloud providers like Amazon Web Services and Google Cloud, as well as in local high-performance computing or hybrid cloud environments, allowing analytics to be brought directly to the data. It supports secure collaboration among distributed research teams with specified access privileges and facilitates the use of over 700 tools and workflows. A notable component is the Seven Bridges GRAF™ Suite, which uses a pan-genome graph reference for more accurate secondary analysis of next-generation sequencing (NGS) data. The platform is compliant with major standards like GDPR and HIPAA, ensuring the security of sensitive patient data. In January 2023, Seven Bridges was acquired by the private equity firm Summa Equity and subsequently merged with Pierian and UgenTec to form a new precision medicine entity called Velsera.